(Q48942338)

17 February 2018

title

Induction of a Th2 immune response by co-administration of recombinant adenovirus vectors encoding amyloid beta-protein and GM-CSF. (English)

1 reference

17 February 2018

1 reference

Hong-Duck Kim

1

1 reference

17 February 2018

Yunpeng Cao

2

1 reference

17 February 2018

Fan-Kun Kong

3

1 reference

17 February 2018

Kent R Van Kampen

4

1 reference

17 February 2018

Terry L Lewis

5

1 reference

17 February 2018

Zhendong Ma

6

1 reference

17 February 2018

De-chu C Tang

7

1 reference

17 February 2018

Ken-Ichiro Fukuchi

8

1 reference

17 February 2018

language of work or name

English

0 references

publication date

1 April 2005

1 reference

17 February 2018

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

17 February 2018

volume

23

1 reference

17 February 2018

issue

23

1 reference

17 February 2018

page(s)

2977-2986

1 reference

17 February 2018

Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Nerve inflammation halts trial for Alzheimer's drug.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Protection against tetanus by needle-free inoculation of adenovirus-vectored nasal and epicutaneous vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

GM-CSF-secreting melanoma vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Determinants of translational fidelity and efficiency in vertebrate mRNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

'Green mice' as a source of ubiquitous green cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Efficient selection for high-expression transfectants with a novel eukaryotic vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Overexpression of a C-terminal portion of the beta-amyloid precursor protein in mouse brains by transplantation of transformed neuronal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Overexpression of amyloid precursor protein alters its normal processing and is associated with neurotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Activity assays of nine heterogeneous promoters in neural and other cultured cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Codon usage tabulated from the international DNA sequence databases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

GM-CSF transgene expression in the airway allows aerosolized ovalbumin to induce allergic sensitization in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

A$beta;1-15 is less immunogenic than A$beta;1-40/42 for intranasal immunization of wild-type mice but may be effective for ?boosting?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.12.015

10.1016/J.VACCINE.2004.12.015

7 January 2021

Identifiers

DOI

1 reference

17 February 2018

1 reference

17 February 2018